Structure Therapeutics reported Phase 2 data showing its oral GLP‑1 candidate aleniglipron produced up to a 16% placebo‑adjusted weight reduction at 44 weeks, positioning the drug as a high‑efficacy oral contender in the obesity market. The company plans to move the program into Phase 3, citing tolerability improvements after implementing a slower dose escalation strategy. Trial investigators randomized patients across dosing regimens and stepped-up participants from low initiation doses to target daily doses over 20 weeks, then continued to 44 weeks; the data include both efficacy and retention metrics. Structure highlighted lower discontinuation rates compared with historic oral GLP‑1 trials after protocol changes reduced early adverse events. The results intensify competition among oral GLP‑1 developers—following recent launches and impending approvals for rival oral formulations—and signal growing investor and regulatory interest in shifting injectable-standard weight‑loss therapies into pill formats. Clinicians and payers will watch safety, cardiovascular outcomes, and Phase 3 design details to assess comparative positioning against established injectables and other oral candidates.